Document is current
Any future updates will be listed below
-
Authors
Zhang, Puhong
Chen, Minyuan
Zhang, Heng
Luo, Yingying
Zhu, Dongshan
Li, Xian
Ji, Jiachao
Wang, Du
Duolikun, Nadila
Ji, Linong
-
Funding
Funding for this research was provided by:
Sanofi China Investment Company (N/A)
- License Information
-
More Information
Article History
Received: 9 October 2020
Accepted: 28 October 2021
First Online: 19 January 2022
Declarations
:
: The ORBIT protocol was approved by the Institutional Review Board (IRB) of Peking University (IRB. No. IRB00001052-11070) which belongs to Peking University, and when necessary, by local IRBs of participating hospitals. Written informed consents were obtained from all patients. Data used in this study was anonymized before its use. Researchers can apply for access to anonymized raw data and associated documents used in this study by contacting the corresponding author. Any cross-border transfer of individual dada must obtain official approval following legal procedures. The export of human related data is governed by the Ministry of Science and Technology of China (MOST) in accordance with the Regulations of the People’s Republic of China on Administration of Human Genetic Resources (State Council No.717).
: Not applicable.
: L. J. reported receiving consulting and lecture fees from Eli Lilly, Bristol-Myers Squibb, Novartis, Novo Nordisk, Merck, Bayer, Takeda, Sanofi, Roche and Boehringer Ingelheim, and research grants from Roche and Sanofi. The other authors declare that they have no conflicts of interest.
